Target Name: CMTM1
NCBI ID: G113540
Other Name(s): Chemokine-like factor superfamily member 1 | CKLF like MARVEL transmembrane domain containing 1 | chemokine-like factor-like protein CKLFH1 | Chemokine-like factor-like protein CKLFH1 | CKLFH | Chemokine-like factor super family 1 | CMTM1 variant 17 | CKLFSF1 | CKLF1_HUMAN | chemokine-like factor super family 1 | CKLF like MARVEL transmembrane domain containing 1, transcript variant 17 | CKLF-like MARVEL transmembrane domain-containing protein 1 | chemokine-like factor superfamily 1 | CKLFH1 | CKLF-like MARVEL transmembrane domain-containing protein 1 (isoform 13) | chemokine-like factor superfamily member 1 | Chemokine-like factor superfamily 1

CMTM1: A Potential Drug Target and Biomarker for Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a type of cancer that affects the bone marrow and blood cells. It is a potentially curable disease, but despite advances in treatment, the survival rate remains high. The treatment options for CML patients are limited and often have significant side effects. Therefore, there is a need for new treatments that can be effective and have fewer side effects.

One potential drug target for CML is CMTM1, a member of the Chemokine-like factor superfamily. CMTM1 is a transmembrane protein that is expressed in various tissues and cells, including the bone marrow, spleen, and lymphoid organs. It has been shown to play a role in the development and progression of CML.

CMTM1 functions as a receptor for the chemokine interleukin-3 (IL-3), which is a cytokine that plays a critical role in the development and maintenance of immune cells. IL-3 has been shown to promote the proliferation and survival of various types of cancer cells, including leukemia cells. Therefore, CMTM1 has been shown to contribute to the development and progression of CML.

In addition to its role in the development of CML, CMTM1 has also been shown to be a potential biomarker for this disease. The presence of CMTM1 in the blood cells of CML patients has been shown to be associated with the disease severity and the response to treatment.

CMTM1 has also been shown to play a role in the regulation of cellular processes that are important for the survival of cancer cells. For example, it has been shown to regulate the expression of genes involved in cell adhesion, migration, and invasion. This suggests that CMTM1 may be a useful target for drugs that can inhibit these processes in cancer cells.

In conclusion, CMTM1 is a potential drug target and biomarker for CML. Further research is needed to understand the full role of CMTM1 in the development and progression of this disease and to identify effective treatments that can be used to target it.

Protein Name: CKLF Like MARVEL Transmembrane Domain Containing 1

More Common Targets

CMTM2 | CMTM3 | CMTM4 | CMTM5 | CMTM6 | CMTM7 | CMTM8 | CMTR1 | CMTR2 | CMYA5 | CNBD1 | CNBD2 | CNBP | CNDP1 | CNDP2 | CNE9 | CNEP1R1 | CNFN | CNGA1 | CNGA2 | CNGA3 | CNGA4 | CNGB1 | CNGB3 | CNIH2 | CNIH3 | CNIH4 | CNKSR1 | CNKSR2 | CNKSR3 | CNMD | CNN1 | CNN2 | CNN2P2 | CNN2P4 | CNN3 | CNN3-DT | CNNM1 | CNNM2 | CNNM3 | CNNM4 | CNOT1 | CNOT10 | CNOT11 | CNOT2 | CNOT3 | CNOT4 | CNOT4P1 | CNOT6 | CNOT6L | CNOT6LP1 | CNOT7 | CNOT8 | CNOT9 | CNP | CNPPD1 | CNPY1 | CNPY2 | CNPY3 | CNPY4 | CNR1 | CNR2 | CNRIP1 | CNST | CNTD1 | CNTF | CNTFR | CNTLN | CNTN1 | CNTN2 | CNTN3 | CNTN4 | CNTN4-AS1 | CNTN4-AS2 | CNTN5 | CNTN6 | CNTNAP1 | CNTNAP2 | CNTNAP2-AS1 | CNTNAP3 | CNTNAP3B | CNTNAP3P2 | CNTNAP4 | CNTNAP5 | CNTRL | CNTROB | COA1 | COA3 | COA4 | COA5 | COA6 | COA6-AS1 | COA7 | COA8 | Coagulation Factor XIII | COASY | Coatomer protein complex | COBL | COBLL1 | COCH